TW202112785A - Shp2抑制劑的固體形式 - Google Patents
Shp2抑制劑的固體形式 Download PDFInfo
- Publication number
- TW202112785A TW202112785A TW109118750A TW109118750A TW202112785A TW 202112785 A TW202112785 A TW 202112785A TW 109118750 A TW109118750 A TW 109118750A TW 109118750 A TW109118750 A TW 109118750A TW 202112785 A TW202112785 A TW 202112785A
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- pharmaceutical composition
- crystalline form
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962858837P | 2019-06-07 | 2019-06-07 | |
| US62/858,837 | 2019-06-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202112785A true TW202112785A (zh) | 2021-04-01 |
Family
ID=71787182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW109118750A TW202112785A (zh) | 2019-06-07 | 2020-06-04 | Shp2抑制劑的固體形式 |
Country Status (15)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI852912B (zh) | 2017-09-07 | 2024-08-21 | 美商銳新醫藥公司 | Shp2抑制劑組合物以及治療癌症的方法 |
| CA3142430A1 (en) | 2019-06-07 | 2020-12-10 | Revolution Medicines, Inc. | Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor |
| TW202313041A (zh) | 2021-06-09 | 2023-04-01 | 瑞士商諾華公司 | 包含達拉菲尼、曲美替尼和shp2抑制劑之三重藥物組合 |
| TW202317100A (zh) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | 包含kras g12c抑制劑的藥物組合及其用於治療癌症之用途 |
| US20240374571A1 (en) | 2021-09-01 | 2024-11-14 | Novartis Ag | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
| EP1871762A2 (en) * | 2005-04-18 | 2008-01-02 | Neurogen Corporation | Subtituted heteroaryl cb1 antagonists |
| NZ623069A (en) | 2009-08-17 | 2015-11-27 | Sloan Kettering Inst Cancer | Heat shock protein binding compounds, compositions, and methods for making and using same |
| JO3517B1 (ar) * | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| ES2699351T3 (es) * | 2014-01-17 | 2019-02-08 | Novartis Ag | Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2 |
| IL311645B2 (en) | 2016-07-12 | 2025-11-01 | Revolution Medicines Inc | 2,5- disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines asallosteric shp2 inhibitors |
| TWI852912B (zh) | 2017-09-07 | 2024-08-21 | 美商銳新醫藥公司 | Shp2抑制劑組合物以及治療癌症的方法 |
| KR20200143417A (ko) | 2018-04-10 | 2020-12-23 | 레볼루션 메디슨즈, 인크. | Shp2 억제제 조성물, 암을 치료하는 방법 및 shp2 돌연변이를 갖는 대상체를 확인하는 방법 |
| CA3142430A1 (en) | 2019-06-07 | 2020-12-10 | Revolution Medicines, Inc. | Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor |
-
2020
- 2020-06-04 CA CA3142430A patent/CA3142430A1/en active Pending
- 2020-06-04 EP EP20746488.4A patent/EP3980128A1/en active Pending
- 2020-06-04 CN CN202080054905.0A patent/CN114190090A/zh active Pending
- 2020-06-04 MX MX2021014855A patent/MX2021014855A/es unknown
- 2020-06-04 PH PH1/2021/552902A patent/PH12021552902A1/en unknown
- 2020-06-04 KR KR1020227000184A patent/KR20220019017A/ko not_active Ceased
- 2020-06-04 TW TW109118750A patent/TW202112785A/zh unknown
- 2020-06-04 BR BR112021022635A patent/BR112021022635A2/pt not_active IP Right Cessation
- 2020-06-04 AU AU2020288631A patent/AU2020288631A1/en not_active Abandoned
- 2020-06-04 CN CN202210564150.XA patent/CN115141205A/zh active Pending
- 2020-06-04 MA MA056113A patent/MA56113A/fr unknown
- 2020-06-04 SG SG11202112461QA patent/SG11202112461QA/en unknown
- 2020-06-04 JP JP2021571896A patent/JP2022534788A/ja active Pending
- 2020-06-04 WO PCT/US2020/036137 patent/WO2020247643A1/en not_active Ceased
-
2021
- 2021-02-26 US US17/187,504 patent/US11220501B2/en active Active
- 2021-11-29 US US17/537,113 patent/US12528807B2/en active Active
- 2021-12-01 IL IL288568A patent/IL288568A/en unknown
-
2025
- 2025-06-18 JP JP2025101917A patent/JP2025138706A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MA56113A (fr) | 2022-04-13 |
| US12528807B2 (en) | 2026-01-20 |
| JP2022534788A (ja) | 2022-08-03 |
| MX2021014855A (es) | 2022-01-18 |
| CN115141205A (zh) | 2022-10-04 |
| EP3980128A1 (en) | 2022-04-13 |
| IL288568A (en) | 2022-02-01 |
| AU2020288631A1 (en) | 2021-12-09 |
| BR112021022635A2 (pt) | 2022-01-04 |
| JP2025138706A (ja) | 2025-09-25 |
| PH12021552902A1 (en) | 2022-04-04 |
| US11220501B2 (en) | 2022-01-11 |
| CN114190090A (zh) | 2022-03-15 |
| WO2020247643A1 (en) | 2020-12-10 |
| KR20220019017A (ko) | 2022-02-15 |
| CA3142430A1 (en) | 2020-12-10 |
| US20210253574A1 (en) | 2021-08-19 |
| SG11202112461QA (en) | 2021-12-30 |
| US20220298159A1 (en) | 2022-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12528807B2 (en) | Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl} methanol, a SHP2 inhibitor | |
| US11191766B2 (en) | Methods of treating pediatric cancers | |
| JP6946194B2 (ja) | キナーゼを調節する化合物の固体形態 | |
| TWI746537B (zh) | (s)-n-(5-((r)-2-(2,5-二氟苯基)-吡咯啶-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羥基吡咯啶-1-甲醯胺之液體調配物 | |
| TWI746426B (zh) | (S)-N-(5-((R)-2-(2,5-二氟苯基)-吡咯啶-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羥基吡咯啶-1-甲醯胺硫酸氫鹽結晶型 | |
| TWI809503B (zh) | Cdk4抑制劑之固體形式 | |
| AU2021272064A1 (en) | Salt and crystal forms of 4-amino-5-(6-(4-methylpiperazin-1-yl)-1H-benzo(d)imidazol-2-yl)thieno(2,3-b)pyridin-6(7H) | |
| JP7689964B2 (ja) | 金属塩及びその使用 | |
| HK40077975A (zh) | Shp2抑制剂的固体形式 | |
| TW201143761A (en) | Tablet formulation of ezatiostat | |
| HK40068870A (en) | Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor | |
| CN114127071A (zh) | 激酶抑制剂的多晶型、含有该化合物的药物组合物、制备方法、及应用 | |
| KR20250073670A (ko) | 카르바메이트 유도체의 형태 및 관련 용도 | |
| TW202440585A (zh) | MDM2-p53抑制劑之晶型及醫藥組合物 | |
| TW202604493A (zh) | Ripk2抑制劑之晶型 | |
| JP2025528490A (ja) | ヘテロアリールオキシナフタレン系化合物の使用 | |
| CN107207540A (zh) | 蛋白酶体抑制剂的新型晶形 | |
| JP2015500809A (ja) | 非晶質エザチオスタット非溶媒和物 |